COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,388 Articles (22,816 medRxiv, 8,572 bioRxiv)

Most recent first Previous |  Page 1006: Articles 10051-10060  | Next

Tuftsin: a natural molecule against SARS-CoV-2 infection
Huang, J., Wang, J., Wang, Z., Chu, M., Wang, Y.
10.1101/2022.01.10.475746 — Posted: 2022-01-17
Increased airborne transmission of COVID-19 with new variants. Implications for health policies.
Rowe, B. R., Canosa, A., Meslem, A., Rowe, F.
10.1101/2022.01.13.22269234 — Posted: 2022-01-17
Sero-Prevalence of Covid-19 among workers in Malaysia
Noordin, N. M., Omar, A., Isharudin, I. H., Idris, R., Chem, Y., Mat Sahat, I. S., Sengol, S., Aziz, Z. A., Lim, Z. z., Lim, T. O.
10.1101/2022.01.16.22269388 — Posted: 2022-01-17
Pooled RNA: extraction free testing of saliva for SARS-CoV-2 detection
Allicock, O. M., Yolda-Carr, D., Todd, J., Wyllie, A. L.
10.1101/2022.01.16.22269390 — Posted: 2022-01-17
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays
Seidel, A., Jahrsdörfer, B., Körper, S., Albers, D., von Maltitz, P., Müller, R., Lotfi, R., Wuchter, P., Klüter, H., Schmidt, M., Münch, J., Schrezenmeier, H.
10.1101/2022.01.17.22269201 — Posted: 2022-01-17
The Impact of State Paid Sick Leave Policies on Longitudinal Weekday Workplace Mobility During the COVID-19 Pandemic
Pollack, C. C., Deverakonda, A., Hassan, F., Haque, S., Desai, A. N., Majumder, M.
10.1101/2022.01.16.22269377 — Posted: 2022-01-17
Evaluation of an emergency safe supply drug and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness
Brothers, T. D., Leaman, M., Bonn, M., Lewer, D., Atkinson, J., Fraser, J., Gillis, A., Gniewek, M., Hawker, L., Hayman, H., Jorna, P., Martell, D., O'Donnell, T., Rivers-Bowerman, H., Genge, L.
10.1101/2022.01.14.22269074 — Posted: 2022-01-17
The statistical analysis of daily data associated with different parameters of the New Coronavirus COVID-19 pandemic in Georgia and their monthly interval prediction from September 1, 2021 to December 31, 2021
Amiranashvili, A. G., Khazaradze, K. R., Japaridze, N. D.
10.1101/2022.01.16.22269373 — Posted: 2022-01-16
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., Peariasamy, K. M., Sivasampu, S.
10.1101/2022.01.15.22269326 — Posted: 2022-01-16
Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant
Jergovic, M., Coplen, C. P., Uhrlaub, J. L., Beitel, S. C., Burgess, J. L., Lutrick, K., Ellingson, K. D., Watanabe, M., Nikolich-Zugich, J.
10.1101/2022.01.16.22269361 — Posted: 2022-01-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).